Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance

Clinical and Experimental Immunology

Volumn 159, Issue 2, 2010, Pages 208-216

  Rearte, B ^a   Landoni, V ^a   Laborde, E ^a   Fernandez G ^b   Isturiz, M ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Dexamethasone; Endotoxin tolerance; Glucocorticoids; LPS; RU486

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; ENDOTOXIN; GLUCOCORTICOID; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MIFEPRISTONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; DEXAMETHASONE; DRUG TOLERANCE; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLUCOCORTICOIDS; HORMONE ANTAGONISTS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MIFEPRISTONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72949114885     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04052.x     Document Type: Article

References (60)

1. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004 329 : 480.
2. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann NY Acad Sci 2008 1144 : 210 236.
3. Rangel-Frausto MS. The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999 13 : 299 312.
4. Shimaoka M, Park EJ. Advances in understanding sepsis. Eur J Anaesthesiol Suppl 2008 42 : 146 153.
5. Zacharowski K, Zacharowski PA, Koch A et al. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 2006 103 : 6392 6397.
6. Bosshart H, Heinzelmann M. Targeting bacterial endotoxin: two sides of a coin. Ann NY Acad Sci 2007 1096 : 1 17.
7. Ianaro A, Tersigni M, D'Acquisto F. New insight in LPS antagonist. Mini Rev Med Chem 2009 9 : 306 317.
8. Opal SM. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 2007 297 : 365 377.
9. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999 13 : 285 297.
10. Carroll JA, Reuter RR, Chase CC et al. Profile of the bovine acute-phase response following an intravenous bolus-dose lipopolysaccharide challenge. Innate Immun 2009 15 : 81 9.
11. Fock RA, Vinolo MA, Crisma AR, Nakajima K, Rogero MM, Borelli P. Protein-energy malnutrition modifies the production of interleukin-10 in response to lipopolysaccharide (LPS) in a murine model. J Nutr Sci Vitaminol (Tokyo) 2008 54 : 371 377.
12. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003 9 : 517 524.
13. Sanchez-Lemus E, Benicky J, Pavel J, Saavedra JM. In vivo angiotensin II AT(1) receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 2009 23 : 945 957.
14. Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotox Res 2003 9 : 3 24.
15. Evans GF, Zuckerman SH. Glucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 1991 21 : 1973 1979.
16. Cavaillon JM. The nonspecific nature of endotoxin tolerance. Trends Microbiol 1995 3 : 320 324.
17. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotox Res 2003 9 : 101 107.
18. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993 328 : 1471 1477.
19. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002 30 : S64 S73.
20. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006 10 : 233.
21. Limaye AP, Kirby KA, Rubenfeld GD et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008 300 : 413 422.
22. Luyt CE, Combes A, Deback C et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007 175 : 935 942.
23. Morrison DC, Silverstein R, Luchi M, Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect Dis Clin North Am 1999 13 : 313 340.
24. Ikeda T, Yang L, Ikenoue T, Mallard C, Hagberg H. Endotoxin-induced hypoxic-ischemic tolerance is mediated by up-regulation of corticosterone in neonatal rat. Pediatr Res 2006 59 : 56 60.
25. Randow F, Syrbe U, Meisel C et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995 181 : 1887 1892.
26. Zuckerman SH, Qureshi N. In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis by Rhodobacter sphaeroides diphosphoryl lipid A is dependent on corticosterone induction. Infect Immun 1992 60 : 2581 2587.
27. Borges BC, Antunes-Rodrigues J, Castro M, Bittencourt JC, Elias CF, Elias LL. Expression of hypothalamic neuropeptides and the desensitization of pituitary-adrenal axis and hypophagia in the endotoxin tolerance. Horm Behav 2007 52 : 508 519.
28. Allary J, Annane D. Glucocorticoids and sepsis. Minerva Anestesiol 2005 71 : 759 768.
29. Annane D, Bellissant E, Bollaert PE et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009 301 : 2362 2375.
30. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intens Care Med 2000 26 (Suppl. 1 S124 8.
31. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009 15 : 496 497.
32. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003 3 : 169 176.
33. Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997 3 : 678 681.
34. National Institutes of Health. Guide for the care and use of laboratory animals. NIH Publication no. 85-23. Bethesda, MD : National Institutes of Health 1985.
35. Wang AM, Creasey AA, Ladner MB et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985 228 : 149 154.
36. Fitting C, Dhawan S, Cavaillon JM. Compartmentalization of tolerance to endotoxin. J Infect Dis 2004 189 : 1295 1303.
37. Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 1994 91 : 271 275.
38. Ziegler-Heitbrock HW. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 1995 45 : 13 26.
39. Zuckerman SH, Evans GF, Butler LD. Endotoxin tolerance: independent regulation of interleukin-1 and tumor necrosis factor expression. Infect Immun 1991 59 : 2774 2780.
40. Benjamim CF, Hogaboam CM, Kunkel SL. The chronic consequences of severe sepsis. J Leukoc Biol 2004 75 : 408 412.
41. Yadavalli GK, Auletta JJ, Gould MP, Salata RA, Lee JH, Heinzel FP. Deactivation of the innate cellular immune response following endotoxic and surgical injury. Exp Mol Pathol 2001 71 : 209 221.
42. Helming L, Bose J, Ehrchen J et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005 106 : 4351 4358.
43. Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A. Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 2008 36 : 848 854.
44. Bergmann M, Gornikiewicz A, Sautner T et al. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock 1999 12 : 421 427.
45. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Chapman MJ, Lesnik P. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock. J Immunol 2008 180 : 6941 6946.
46. Pachot A, Cazalis MA, Venet F et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol 2008 180 : 6421 6429.
47. Bjorkbacka H, Fitzgerald KA, Huet F et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 2004 19 : 319 330.
48. Medvedev AE, Kopydlowski KM, Vogel SN. Inhibition of lipopolysaccharide- induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 2000 164 : 5564 5574.
49. Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med 1988 168 : 95 105.
50. Ogle CK, Guo X, Chance WT, Ogle JD. Induction of endotoxin tolerance in rat bone marrow cells by in vivo infusion of tumor necrosis factor. Crit Care Med 1997 25 : 827 833.
51. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998 94 : 557 572.
52. Beer HD, Fassler R, Werner S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000 59 : 217 239.
53. Alves-Rosa F, Vulcano M, Beigier-Bompadre M, Fernandez G, Palermo M, Isturiz MA. Interleukin-1beta induces in vivo tolerance to lipopolysaccharide in mice. Clin Exp Immunol 2002 128 : 221 228.
54. Berg DJ, Kuhn R, Rajewsky K et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995 96 : 2339 2347.
55. Zingarelli B, Hake PW, Cook JA. Inducible nitric oxide synthase is not required in the development of endotoxin tolerance in mice. Shock 2002 17 : 478 484.
56. Baykal A, Kaynaroglu V, Hascelik G, Sayek I, Sanac Y. Epinephrine and endotoxin tolerance differentially modulate serum cytokine levels to high-dose lipopolysaccharide challenge in a murine model. Surgery 1999 125 : 403 410.
57. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994 120 : 771 783.
58. Koldzic-Zivanovic N, Tu H, Juelich TL et al. Regulation of adrenal glucocorticoid synthesis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona fasciculata. Brain Behav Immun 2006 20 : 460 468.
59. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma 2005 58 : 867 874.
60. Meisel C, Schefold JC, Pschowski R et al. GM-CSF to reverse sepsis-associated immunosuppression: a double-blind randomized placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009 180 : 640 648.